In a significant move, the U.S. Department of Justice (DOJ) has proposed that Alphabet&rsquo;s Google divest two of its key advertising technologies&mdash;AdX (Ad Exchange) and its ad server platform, DFP (DoubleClick for Publishers). This comes after a federal judge determined that the tech giant had unlawfully dominated two critical online advertising markets, putting its antitrust practices under intense scrutiny.
&nbsp;
The DOJ&rsquo;s proposed remedy was unveiled in a court filing on May 05, marking a new chapter in a legal battle that could reshape the landscape of online advertising. The Justice Department argues that Google&rsquo;s monopoly over the ad-exchange and publisher ad-server markets has stifled competition, and the divestitures are necessary to restore a level playing field.
&nbsp;
The judge set a September trial date on May 02, after hearing from Google and the DOJ on potential remedies for the company's dominance in ad tools used by online publishers.
<h2>What is the issue?</h2>
At the heart of this case is the claim that Google's control over AdX, an online marketplace where publishers sell their unsold ad space in real time, and DFP, a platform used by websites to manage their digital ad inventory, has given the company an unfair advantage. Together, these tools play a pivotal role in how news publishers, content providers, and advertisers interact, allowing Google to dominate the market and suppress competition.
<h2>Google&rsquo;s stance</h2>
Google, however, insists that its practices are not monopolistic and that the company supported behavioural remedies such as making real-time bids available to competitors, but that prosecutors cannot legally pursue a bid to force it to sell parts of its business.
&nbsp;
"The DOJ's additional proposals to force a divestiture of our ad tech tools go well beyond the Court's findings, have no basis in law, and would harm publishers and advertisers," Lee-Anne Mulholland, Google's Vice President of Regulatory Affairs, said in a statement to Reuters.
<h2>Playing monopoly?</h2>
The dispute between Google and the DOJ is not an isolated case. Last year, Google took a major step to resolve an antitrust investigation in the European Union by offering to sell AdX. However, European publishers rejected the offer, stating that it would not go far enough to resolve the competitive concerns in the ad-tech ecosystem.
&nbsp;
The issue of monopolistic practices in digital advertising has been a point of contention for years, as the rise of Google&rsquo;s advertising platforms has increasingly marginalised smaller competitors.
&nbsp;
As the September trial date approaches, all eyes will be on the court's decision and whether it will force Google to relinquish control of its key ad-tech assets. The outcome could have far-reaching implications for the future of digital advertising and the competitive dynamics between publishers, advertisers, and tech giants.

Business & Economy: The U.S. Department of Justice has proposed that Google divest two of its key advertising technologies—AdX (Ad Exchange) and DFP

In a significant move, the U.S. Department of Justice (DOJ) has proposed that Alphabet’s Google divest two of its key advertising technologies—AdX (Ad Exchange) and its ad server platform, DFP (DoubleClick for Publishers). This comes after a federal judge determined that the tech giant had unlawfully dominated two critical online advertising markets, putting its antitrust practices under intense scrutiny. The DOJ’s proposed remedy was unveiled in a court filing on May 05, marking a new chapter in a legal battle that could reshape the landscape of online advertising. The Justice Department argues that Google’s monopoly over the ad-exchange and publisher ad-server markets has stifled competition, and the divestitures are necessary to restore a level playing field. The judge set a September trial date on May 02, after hearing from Google and the DOJ on potential remedies for the company's dominance in ad tools used by online publishers. What is the issue? At the heart of this case is the claim that Google's control over AdX, an online marketplace where publishers sell their unsold ad space in real time, and DFP, a platform used by websites to manage their digital ad inventory, has given the company an unfair advantage. Together, these tools play a pivotal role in how news publishers, content providers, and advertisers interact, allowing Google to dominate the market and suppress competition. Google’s stance Google, however, insists that its practices are not monopolistic and that the company supported behavioural remedies such as making real-time bids available to competitors, but that prosecutors cannot legally pursue a bid to force it to sell parts of its business. "The DOJ's additional proposals to force a divestiture of our ad tech tools go well beyond the Court's findings, have no basis in law, and would harm publishers and advertisers," Lee-Anne Mulholland, Google's Vice President of Regulatory Affairs, said in a statement to Reuters. Playing monopoly? The dispute between Google and the DOJ is not an isolated case. Last year, Google took a major step to resolve an antitrust investigation in the European Union by offering to sell AdX. However, European publishers rejected the offer, stating that it would not go far enough to resolve the competitive concerns in the ad-tech ecosystem. The issue of monopolistic practices in digital advertising has been a point of contention for years, as the rise of Google’s advertising platforms has increasingly marginalised smaller competitors. As the September trial date approaches, all eyes will be on the court's decision and whether it will force Google to relinquish control of its key ad-tech assets. The outcome could have far-reaching implications for the future of digital advertising and the competitive dynamics between publishers, advertisers, and tech giants.

US pushes for Google to divest key ad-tech products after antitrust ruling

The US&nbspSupreme Court sided with the Trump administration and against China on Thursday on a disputed aspect of their fraught trade relationship, throwing out a lower court ruling that had allowed two Chinese vitamin C makers to escape $148 million in damages for violating American antitrust law.

In a case that brought the trade conflict between the world's two largest economies before the top US&nbspcourt, the justices ruled 9-0 that the lower court gave too much deference to Chinese government filings in the case explaining China's regulatory policy.

The justices sent the case back for reconsideration by the New York-based 2nd US&nbspCircuit Court of Appeals, which in 2016 threw out the damages won by two American vitamin C buyers.

Writing for the court, Justice Ruth Bader Ginsburg wrote that while US&nbspcourts should give "respectful consideration" to a foreign government's interpretation of its own law, they are not "bound to accord conclusive effect to the foreign government's statements."

Lawyers for the US&nbspand Chinese governments faced off in April before the justices. The Supreme Court took the unusual step of letting China present arguments even though it is not an official party in the case, a privilege typically reserved for the US&nbspJustice Department.

The price-fixing case dates back to 2005 when Texas-based Animal Science Products Inc and New Jersey-based The Ranis Co Inc accused Hebei Welcome Pharmaceutical and North China Pharmaceutical Group and other Chinese vitamin C makers of antitrust violations.

China intervened in the case, asking the trial court to dismiss the allegations in part because its laws had forced Chinese companies to comply with government-mandated pricing regimes.

A US&nbspfederal judge questioned the credibility of the Chinese submissions and, after a 2013 jury trial, awarded the two American companies $147.8 million in damages.

The New York-based 2nd U.S. Circuit Court of Appeals overturned the judgment in 2016, saying that when a foreign government directly participates in a case American courts are obligated to defer to that country's characterization of its own laws.

The Supreme Court itself did not weigh in on the correct interpretation of Chinese law, but Ginsburg said questions remained over "whether Chinese law required the Chinese sellers' conduct."

China and the United States are locked in a simmering trade dispute. President Donald Trump has accused China of unfair trade practices and threatened to impose tariffs on up to $150 billion in Chinese goods over allegations of intellectual property theft. China has warned of retaliation.

In a case that brought the trade conflict between the world's two largest economies before the top US court, the justices ruled 9-0 that the lower court gave too much deference to Chinese government filings in the case explaining China's regulatory policy.

The US&nbspSupreme Court sided with the Trump administration and against China on Thursday on a disputed aspect of their fraught trade relationship, throwing out a lower court ruling that had allowed two Chinese vitamin C makers to escape $148 million in damages for violating American antitrust law. In a case that brought the trade conflict between the world's two largest economies before the top US&nbspcourt, the justices ruled 9-0 that the lower court gave too much deference to Chinese government filings in the case explaining China's regulatory policy. The justices sent the case back for reconsideration by the New York-based 2nd US&nbspCircuit Court of Appeals, which in 2016 threw out the damages won by two American vitamin C buyers. Writing for the court, Justice Ruth Bader Ginsburg wrote that while US&nbspcourts should give "respectful consideration" to a foreign government's interpretation of its own law, they are not "bound to accord conclusive effect to the foreign government's statements." Lawyers for the US&nbspand Chinese governments faced off in April before the justices. The Supreme Court took the unusual step of letting China present arguments even though it is not an official party in the case, a privilege typically reserved for the US&nbspJustice Department. The price-fixing case dates back to 2005 when Texas-based Animal Science Products Inc and New Jersey-based The Ranis Co Inc accused Hebei Welcome Pharmaceutical and North China Pharmaceutical Group and other Chinese vitamin C makers of antitrust violations. China intervened in the case, asking the trial court to dismiss the allegations in part because its laws had forced Chinese companies to comply with government-mandated pricing regimes. A US&nbspfederal judge questioned the credibility of the Chinese submissions and, after a 2013 jury trial, awarded the two American companies $147.8 million in damages. The New York-based 2nd U.S. Circuit Court of Appeals overturned the judgment in 2016, saying that when a foreign government directly participates in a case American courts are obligated to defer to that country's characterization of its own laws. The Supreme Court itself did not weigh in on the correct interpretation of Chinese law, but Ginsburg said questions remained over "whether Chinese law required the Chinese sellers' conduct." China and the United States are locked in a simmering trade dispute. President Donald Trump has accused China of unfair trade practices and threatened to impose tariffs on up to $150 billion in Chinese goods over allegations of intellectual property theft. China has warned of retaliation.

US Supreme Court hands Trump win in China antitrust case

american-antitrust-law

American Antitrust Law, News on American Antitrust Law, stories on American Antitrust Law, articles on American Antitrust Law, American Antitrust Law stories at Wion, American Antitrust Law news, American Antitrust Law latest news

american antitrust-law

US pushes for Google to divest key ad-tech products after antitrust ruling

US Supreme Court hands Trump win in China antitrust case